{"id":390503,"date":"2018-12-31T00:00:00","date_gmt":"2018-12-31T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0006-2018-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-03-31T10:47:28","modified_gmt":"2026-03-31T10:47:28","slug":"dlsfon0006-2018-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0006-2018-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Non-Hodgkin&#8217;s Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"<p>The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin\u2019s lymphoma (<abbr data-original-title=\"non-Hodgkin's lymphoma\" title=\"\">NHL<\/abbr>) therapy market over the ten-year forecast period. One of these novel therapies is Yescarta, the first chimeric antigen receptor (<abbr data-original-title=\"chimeric antigen receptor\" title=\"\">CAR<\/abbr>) T-cell therapy; it is approved for relapsed\/refractory (<abbr data-original-title=\"relapsed\/refractory\" title=\"\">R\/R<\/abbr>) diffuse large B-cell lymphoma\u00a0(<abbr data-original-title=\"diffuse large B-cell lymphoma\" title=\"\">DLBCL<\/abbr>)\u00a0and represents\u00a0a significant milestone in\u00a0<abbr data-original-title=\"non-Hodgkin's lymphoma\" title=\"\">NHL<\/abbr>\u00a0drug development. Offsetting this market growth will be the biosimilar erosion expected for rituximab, the patient-, and market-share leader in 2017\u00a0in the\u00a0<abbr data-original-title=\"non-Hodgkin's lymphoma\" title=\"\">NHL<\/abbr>\u00a0space, and the generic erosion of Revlimid (and, to a lesser extent, bendamustine). Untapped clinical and commercial potential remains in\u00a0<abbr data-original-title=\"non-Hodgkin's lymphoma\" title=\"\">NHL<\/abbr>\u00a0for therapies with improved efficacy and for agents positioned in patient segments that are currently underserved.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>Kinase inhibitors have changed the\u00a0<abbr data-original-title=\"non-Hodgkin's lymphoma\" title=\"\">NHL<\/abbr>\u00a0treatment algorithm since their recent approval.\u00a0<b>Which other kinase inhibitors are most promising in\u00a0<abbr data-original-title=\"non-Hodgkin's lymphoma\" title=\"\">NHL<\/abbr>, and what patient populations will they target? What will be their impact on the\u00a0<abbr data-original-title=\"non-Hodgkin's lymphoma\" title=\"\">NHL<\/abbr>\u00a0market?<\/b><\/li>\n<li>Rituxan\/MabThera is widely used in all\u00a0<abbr data-original-title=\"non-Hodgkin's lymphoma\" title=\"\">NHL<\/abbr>\u00a0drug-treated populations and garners significant sales.\u00a0<b>How will market share for rituximab change over our ten-year forecast period as a result of biosimilars? Will Gazyva\/Gazyvaro achieve the same status as Rituxan\/MabThera within the\u00a0<abbr data-original-title=\"non-Hodgkin's lymphoma\" title=\"\">NHL<\/abbr>\u00a0space and thus minimize the impact of biosimilar erosion of branded rituximab?<\/b><\/li>\n<li>The\u00a0<abbr data-original-title=\"non-Hodgkin's lymphoma\" title=\"\">NHL<\/abbr>\u00a0therapy market will experience robust growth through 2027.\u00a0<b>What factors are driving this growth? Which drug class will dominate the treatment of\u00a0<abbr data-original-title=\"non-Hodgkin's lymphoma\" title=\"\">NHL<\/abbr>? What new classes of agents will emerge over the ten-year forecast period, and what will be their market impact?<\/b><\/li>\n<\/ul>\n<p><strong>Scope:<\/strong><\/p>\n<p><b>Markets covered:<\/b>\u00a0United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/p>\n<p><b>Primary research:<\/b>\u00a020\u00a0country-specific interviews with experts and 210\u00a0country-specific surveys with hematologist-oncologists treating\u00a0<abbr data-original-title=\"non-Hodgkin's lymphoma\" title=\"\">NHL<\/abbr>.<\/p>\n<p><b>Epidemiology:<\/b>\u00a0Diagnosed incidence of follicular lymphoma (<abbr data-original-title=\"follicular lymphoma\" title=\"\">FL<\/abbr>) (including transformed\u00a0<abbr data-original-title=\"follicular lymphoma\" title=\"\">FL<\/abbr>), chronic lymphocytic leukemia\/small lymphocytic lymphoma (<abbr data-original-title=\"chronic lymphocytic leukemia\" title=\"\">CLL<\/abbr>\/<abbr data-original-title=\"small lymphocytic lymphoma\" title=\"\">SLL<\/abbr>),\u00a0<abbr data-original-title=\"diffuse large B-cell lymphoma\" title=\"\">DLBCL<\/abbr>, and mantle cell lymphoma (<abbr data-original-title=\"mantle cell lymphoma\" title=\"\">MCL<\/abbr>).<\/p>\n<p><b>Population segments in market forecast:<\/b>\u00a0First line, second line, and third\/fourth line for\u00a0<abbr data-original-title=\"follicular lymphoma\" title=\"\">FL<\/abbr>,\u00a0<abbr data-original-title=\"chronic lymphocytic leukemia\" title=\"\">CLL<\/abbr>\/<abbr data-original-title=\"small lymphocytic lymphoma\" title=\"\">SLL<\/abbr>,\u00a0<abbr data-original-title=\"diffuse large B-cell lymphoma\" title=\"\">DLBCL<\/abbr>, and\u00a0<abbr data-original-title=\"mantle cell lymphoma\" title=\"\">MCL<\/abbr>.<\/p>\n<p><b>Emerging therapies:\u00a0<\/b>Phase I and II: 45\u00a0drugs; Phase III: 10\u00a0drugs; registered: 5\u00a0drugs.<\/p>\n","protected":false},"template":"","class_list":["post-390503","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hodgkins-lymphoma","biopharma-therapy-areas-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390503","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390503\/revisions"}],"predecessor-version":[{"id":393627,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390503\/revisions\/393627"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}